𝔖 Bobbio Scriptorium
✦   LIBER   ✦

High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia

✍ Scribed by G. Heil; P. S. Mitrou; D. Hoelzer; M. Freund; H. Link; G. Ehninger; B. Steinke; S. Öhl; H. Wandt; E. Fackler-Schwalbe; G. Schlimok; A. Lösch; W. Queißer; B. Löffler; W. Gaus; J. Högel; H. Heimpel; E. Kurrle

Publisher
Springer
Year
1995
Tongue
English
Weight
746 KB
Volume
71
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-dose cytosine arabinoside: Clinical
High-dose cytosine arabinoside: Clinical response to therapy in acute leukemia
✍ Early, A. P. ;Preisler, H. D. ;Higby, D. J. ;Brecher, M. ;Browman, G. ;McBride, 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 664 KB

High dose cytosine arabinoside (HD-AraC) was evaluated 1) as remission induction therapy for refractory acute leukemia and high risk AML, 2) as augmentation therapy for acute leukemia, and 3) as conditioning therapy prior to allogeneic bone marrow transplantation for acute leukemia. Seven of 10 pati

Acute polyneuropathy after high dose cyt
Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia
✍ Harry Openshaw; Neal E. Slatkin; Anthony S. Stein; David R. Hinton; Stephen J. F 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 699 KB

## BACKGROUND. Peripheral nerve toxicity has been reported but is not a commonly recognized complication of high dose cytosine arabinoside (HDAC) therapy. This study was undertaken to estimate the prevalence and describe the clinical spectrum of acute polyneuropathy associated with HDAC therapy fo